Concord Biotech Limited has published extracts of its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, in newspapers as required under SEBI regulations.

Regulatory Compliance and Publication Details

The pharmaceutical company published the financial results extracts on February 12, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were published in two editions to ensure broad accessibility.

Q3FY26 Financial Performance

The company's unaudited financial results for the quarter ended December 31, 2025, show strong operational performance across both standalone and consolidated metrics. The results were reviewed by the Audit Committee and approved by the Board of Directors on February 11, 2026.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, Concord Biotech demonstrated consistent performance with total income from operations reaching ₹72,917.90 lakhs on a standalone basis and ₹72,881.11 lakhs on a consolidated basis.

Management and Governance

The financial results were digitally signed by Mr. Sudhir Kumar Vaid, Chairman & Managing Director (DIN: 00055967), on February 12, 2026. The communication was sent from the company's registered office in Ahmedabad, Gujarat, ensuring proper corporate governance protocols were followed.

In accordance with Regulation 46 of the Listing Regulations, the complete unaudited financial results have been uploaded on the company's official website at www.concordbiotech.com , providing stakeholders with comprehensive access to detailed financial information.

Concord Biotech Limited has informed stock exchanges about the resignation of its Company Secretary and Compliance Officer, marking a key managerial personnel change at the pharmaceutical company.

Key Personnel Change

Ms. Hina Patel has tendered her resignation from the position of Company Secretary and Compliance Officer (Key Managerial Personnel) of Concord Biotech Limited. The resignation was formally communicated to the National Stock Exchange of India Limited and BSE Limited on December 24, 2025, in compliance with regulatory requirements.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The disclosure follows the prescribed format under Regulation 30(6) and Schedule III Para A(7C) of the listing regulations.

Transition Arrangements

In her resignation letter dated December 24, 2025, Ms. Patel expressed gratitude for the trust, guidance, and support extended during her association with the company. She described her tenure as both professionally enriching and personally fulfilling. The outgoing Company Secretary has assured full cooperation during the transition period to ensure a smooth handover of responsibilities.

The company has been requested to file necessary forms with the Registrar of Companies, Ministry of Corporate Affairs, and submit intimations to stock exchanges as part of the resignation process. Ms. Patel extended her best wishes for the continued success of Concord Biotech Limited and expressed hope that the company achieves greater milestones in the future.